Ovarian Cancer
Expression Genetics, Inc. Receives Orphan Drug Grant from FDA for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer
Published in Genomics and Genetics Weekly, May 18th, 2007
Expression Genetics, Inc. announced that the Food and Drug Administration (FDA) has awarded the company a three-year grant of $1,050,000 to assist in the clinical development of EGEN-001, the company's lead product. EGEN-001 is under development for the treatment of advanced recurrent ovarian cancer. The product has recently completed a Phase I trial and is advancing toward expanded clinical testing to evaluate safety and efficacy of the drug when administered in combination with standard chemotherapy treatment. EGEN-001 received Orphan Drug Status from the FDA in 2005.
"This is a significant milestone and accomplishment for the company," commented Dr. Danny H. Lewis,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
More Articles from Genomics and Genetics Weekly
- Asthma
Eight plants from South Africa may hold potential for treating high blood pressure - Autism
No link found between autism and celiac disease - Bird Flu
Researchers create interactive map with Google technology to track avian flu spread - Cold Spring Harbor Protocols
A rainbow of methods promises insights into biological processes and diseases - Fibrosis
Early onset of poor bone mineralization revealed in children with cystic fibrosis - Genetics & Genomics
Digesting Protein May be a Hidden Problem for Some - More from this issue of Genomics and Genetics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
